News and Trends 6 Dec 2014
Alizé Pharma Acquires Exclusive Worldwide Rights on a New Peptide to Tackle Bone Diseases
Alizé Pharma III SAS, an Alizé Pharma group company specialized in the development of biopharmaceuticals to treat metabolic disorders and rare diseases has acquired exclusive worldwide rights to develop and commercialize a new family of peptides with bone anabolic properties. The peptides are derived from a fragment of a physiological protein, called IGFBP-2 (Insulin-like Growth Factor Binding Protein-2). In vitro […]